Intrinsic Therapeutics enrolls 400th Patient in Barricaid Randomized Trial

Intrinsic Therapeutics Announces the Enrollment of the 400th Patient in Landmark Barricaid® Randomized Trial (press release)
Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal of demonstrating fewer disc rehernia...


Your friends are reading OrthoStreams daily - Are you ?

 

Unlock your access to full rich article, trends, hot startups, market reports and your daily newsletter.

Just $1/day.